Latest news

Debiopharm signs international license agreements for Sanvar®

Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas

Debiopharm and EPFL honour Dr Eduard Batlle with the “Debiopharm Life Sciences Award”

The Japanese Cancer Association (JCA) and Debiopharm honour Professors Masanori Hatakeyama and Johji Inazawa with the 2006 JCA-Mauvernay Award

Debiopharm granted European Orphan Drugs Status for Debio-0513 (PTR-262) for Myasthenia Gravis

Debiopharm and Salix pharmaceuticals sign license agreement for Sanvar®

Debiopharm applies for first europe marketing authorisation for Sanvar® in France

Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets

Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men